Selected article for: "early stage and efficacy study"
Author: Zhu, Zhen-Hong; Song, Wen-Qi; Zhang, Chang-Qing; Yin, Ji-Min
Title: Dimethyloxaloylglycine increases bone repair capacity of adipose-derived stem cells in the treatment of osteonecrosis of the femoral head
  • Document date: 2016_9_13
    • ID: kjvy2c2k_32
    Snippet: DMOG is a small molecular drug, which is able to stabilize the expression of HIF-1α in cells (21) . At normal oxygen tension, HIF-1α is modified by oxygen dependent prolyl hydroxylases, resulting in rapid degradation through the ubiquitin-proteasome pathway (22) . Under hypoxic conditions, prolyl hydroxylase activity decreases and HIF-1α is stabilized (39) . DMOG is able to inhibit prolyl hydroxylase activity at normal oxygen tension, thus lea.....
    Document: DMOG is a small molecular drug, which is able to stabilize the expression of HIF-1α in cells (21) . At normal oxygen tension, HIF-1α is modified by oxygen dependent prolyl hydroxylases, resulting in rapid degradation through the ubiquitin-proteasome pathway (22) . Under hypoxic conditions, prolyl hydroxylase activity decreases and HIF-1α is stabilized (39) . DMOG is able to inhibit prolyl hydroxylase activity at normal oxygen tension, thus leading to HIF-1α overexpression in cells. DMOG has been used to treat ischemic skeletal muscles, middle cerebral artery occlusion and ischemic myocardial injury, and all resulted in good outcomes in previous experiments (40) (41) (42) . Our previous study showed that DMOG could significantly enhance VEGF production in ASCs and improved the osteogenic differentiation potential of ASCs in vitro by stabilizing the expression of HIF-1α in ASCs, and DMOG-treated ASCs had an increased bone healing capacity and promoted local revascularization in critical defects (22) . In the present study, we investigated the efficacy of implanting DMOG-treated ASCs to treat early-stage corticosteroid-induced ONFH.

    Search related documents:
    Co phrase search for related documents
    • artery occlusion and previous study: 1, 2, 3
    • ASCs expression and present study: 1, 2
    • bone healing and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • bone healing and previous study: 1, 2
    • bone healing and prolyl hydroxylase: 1
    • bone healing capacity and present study: 1, 2
    • bone healing capacity and previous study: 1
    • bone healing capacity and prolyl hydroxylase: 1
    • cell overexpression and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • cerebral artery occlusion and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • cerebral artery occlusion and previous study: 1, 2, 3
    • corticosteroid induce and present study: 1
    • critical defect and present study: 1
    • differentiation potential and present study: 1, 2, 3, 4, 5, 6, 7
    • early stage and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • early stage and previous study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • early stage and prolyl hydroxylase: 1
    • good outcome and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • good outcome and previous study: 1